公开(公告)号：US20240307538A1

公开(公告)日：2024-09-19

申请号：US18551156

申请日：2022-03-18

Applicant: UNIVERSITE TOULOUSE III - PAUL SABATIER ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER ,  UNIVERSITE DE MONTPELLIER ,  ARTHRITIS RECHERCHE & DEVELOPPEMENT

Inventor： Cyril CLAVEL ,  Guy Bruno René SERRE ,  Pierre MARTINEAU ,  Nerea ALLENDE-VEGA ,  Florence APPARAILLY ,  Martin VILLALBA ,  Christian JORGENSEN

IPC: A61K39/00 ,  C07K14/735 ,  C07K14/75 ,  C12N5/0783 ,  C12N5/0786

CPC classification number: A61K39/46433 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4621 ,  C07K14/70535 ,  C07K14/75 ,  C12N5/0645 ,  C12N5/0646 ,  C07K2319/30 ,  C12N2510/00

Abstract: The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

公开(公告)号：US20230405118A1

公开(公告)日：2023-12-21

申请号：US18251060

申请日：2021-10-29

Applicant: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION

Inventor： Alejandro VILLAGRA ,  Satish NOONEPALLE ,  Maria del Mar Gracia HERNANDEZ

IPC: A61K39/00 ,  C12N5/0786 ,  A61K35/15 ,  A61K45/06

CPC classification number: A61K39/4614 ,  C12N5/0645 ,  A61K39/464495 ,  A61K39/464491 ,  A61K39/464486 ,  A61K39/464488 ,  A61K39/46449 ,  A61K39/464482 ,  A61K39/464481 ,  A61K39/46447 ,  A61K39/464456 ,  A61K39/464451 ,  A61K39/4644 ,  A61K35/15 ,  A61K45/06 ,  C12N2501/2304 ,  C12N2501/2313 ,  A61K2039/5154

Abstract: The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods of making STAT-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of STAT-activated macrophages.

公开(公告)号：US20230293685A1

公开(公告)日：2023-09-21

申请号：US17997648

申请日：2021-05-04

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Michelle Simpson-Abelson ,  Arvind Natarajan

IPC: A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/55 ,  C07K16/28 ,  A61K31/664 ,  A61K31/7076 ,  C12N5/0783

CPC classification number: A61K39/4611 ,  C07K14/70521 ,  C07K14/70596 ,  C07K14/70546 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/55 ,  C07K16/2818 ,  C07K14/70517 ,  A61K39/4633 ,  A61K39/464429 ,  A61K39/464411 ,  A61K39/4632 ,  A61K39/4635 ,  A61K39/4622 ,  A61K39/4614 ,  A61K31/664 ,  A61K31/7076 ,  C12N5/0636 ,  C07K2317/21 ,  C07K2317/14 ,  C07K2317/52 ,  C07K2317/24 ,  C12N2501/2302

Abstract: The present invention provides methods for preselecting TILs based on PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT expression, as well as methods for expanding those preselected PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).

公开(公告)号：US20240350629A1

公开(公告)日：2024-10-24

申请号：US18681457

申请日：2022-08-12

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Young Jik Kwon ,  Jee Young Chung

IPC: A61K39/00 ,  A61K39/215 ,  A61P37/04

CPC classification number: A61K39/4622 ,  A61K39/215 ,  A61K39/4612 ,  A61K39/4614 ,  A61K39/4615 ,  A61K39/4641 ,  A61K39/4644 ,  A61K39/4648 ,  A61K39/464838 ,  A61P37/04

Abstract: The disclosure provides for compositions and methods comprising cell-derived vesicles induced from cells that have been genetically engineered or infected to express specific antigen(s), and uses thereof, including as a cell-free, cell-like vaccine.

公开(公告)号：US20240156963A1

公开(公告)日：2024-05-16

申请号：US18302636

申请日：2023-04-18

Applicant: Wisconsin Alumni Research Foundation

Inventor： James Thomson ,  Jue Zhang ,  Igor Slukvin ,  Aditi Majumder ,  Ho Sun Jung

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/0787

CPC classification number: A61K39/464471 ,  A61K39/461 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/3084 ,  C12N5/0642 ,  C12N5/0645 ,  C12N5/0646 ,  C12N2506/45 ,  C12N2510/00

Abstract: This disclosure provides genetically engineered immune cells that express an anti-GD2 chimeric antigen receptor, methods of generating these cells, and methods of treating tumors using the genetically engineered cells.

公开(公告)号：US20240148868A1

公开(公告)日：2024-05-09

申请号：US18282503

申请日：2022-03-17

Applicant: University of Florida Research Foundation, Incorporated

Inventor： Todd Eliot Golde ,  Marshall S. Goodwin ,  Brenda Dawn Moore ,  Thomas B. Ladd ,  Yong Ran ,  Yona Levites ,  Pedro Cruz

IPC: A61K39/00 ,  A61K48/00 ,  A61P25/28 ,  C07K14/705 ,  C07K16/18 ,  C12N15/86

CPC classification number: A61K39/4614 ,  A61K39/4633 ,  A61K39/4643 ,  A61K48/0058 ,  A61P25/28 ,  C07K14/70503 ,  C07K16/18 ,  C12N15/86 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/43 ,  C12N2750/14143

Abstract: Provided herein are chimeric receptors, engineered cells and pharmaceutical compositions for enhancement of long-term clearance of protein aggregates in the central nervous system via phagocytosis or engulfment. Further provided herein are methods of treatment of subjects suffering from, or diagnosed with, a neurodegenerative disease by administering these receptors, modified cells, and/or pharmaceutical compositions. Administration of one or more, or a plurality of these modified cells, to a subject may provide treatment of a neurodegenerative disease such as Alzheimer's Disease (AD) or Parkinson's Disease (PD). Advantageously, the modified cells, pharmaceutical compositions, and methods of the present disclosure meet existing needs in the art by providing clearance of accumulations of protein aggregates in brain tissue in PD and AD pathologies.

公开(公告)号：US20230374538A1

公开(公告)日：2023-11-23

申请号：US18188027

申请日：2023-03-22

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Yuxiao WANG ,  Namita BISARIA ,  Inna SHCHERBAKOVA ,  William F. ROWLEY, JR.

IPC: C12N15/85 ,  A61K39/00 ,  A61K48/00

CPC classification number: C12N15/85 ,  A61K39/4614 ,  A61K39/4631 ,  A61K48/0066 ,  C12N2830/50

Abstract: Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.

公开(公告)号：US20230364049A1

公开(公告)日：2023-11-16

申请号：US18246585

申请日：2021-09-24

Applicant: VIB VZW ,  KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D

Inventor： Massimiliano MAZZONE

IPC: A61K31/26 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K31/26 ,  A61K39/3955 ,  A61K39/4646 ,  A61K39/4614 ,  A61P35/00

Abstract: The invention is situated in the field of cancer treatment. In particular it relates to treatments comprising combining an inhibitor of the pyrimidinergic receptor P2Y6 and an immune checkpoint inhibitor. Further in particular, the treatment is of benefit for cancers poorly responding to immune checkpoint inhibitor therapy.

公开(公告)号：US20230338529A1

公开(公告)日：2023-10-26

申请号：US18019627

申请日：2021-08-05

Applicant: The Children's Medical Center Corporation

Inventor： Zhigang HE ,  Yi LI ,  Xuelian HE

IPC: A61K31/336 ,  A61K39/00 ,  A61P17/02 ,  A61K38/55 ,  A61K31/404 ,  A61P25/00

CPC classification number: A61K39/4614 ,  A61K31/336 ,  A61K31/404 ,  A61K38/55 ,  A61K39/4633 ,  A61K39/4637 ,  A61K39/464 ,  A61K39/4644 ,  A61K39/464402 ,  A61K39/464429 ,  A61P17/02 ,  A61P25/00

Abstract: Provided herein are compositions and methods for reducing neuroinflammation and treating neurodegenerative diseases using proteinase inhibitors. The invention also provides methods for reducing post-injury scar formation in the central nervous system.

公开(公告)号：US20240325532A1

公开(公告)日：2024-10-03

申请号：US18617973

申请日：2024-03-27

Applicant: Novocure GmbH

Inventor： Tali Voloshin-Sela ,  Tal Kan ,  Yiftah Barsheshet ,  Lilach Avigdor

IPC: A61K39/00 ,  A61N1/40 ,  A61P35/00

CPC classification number: A61K39/4631 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61K39/464404 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464468 ,  A61K39/46447 ,  A61K39/464482 ,  A61K39/464493 ,  A61N1/40 ,  A61P35/00

Abstract: Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition comprising at least one chimeric antigen receptor (CAR)-immune cell.